产品说明
Formulation50%(vol/vol)Glycerol/H2OMolecularWeightStorage-20°CPurity>95%bySDS-PAGECompoundAssayThrombininhibitionShelfLife(properlystored)12monthsChemicalFormulaInhibitionofThrombinbyHeparinCofactorIIThrombin(IIa),heparin(HEP)andheparincofactorII(HCII)interacttoformaternarycomplexviaarandomorderbireactantmechanism.HeparinsubsequentlydissociatesfromthecomplexasthrombinformsacovalentcomplexwiththeheparincofactorII.SampleGelInformation:GelNovex4-12%Bis-TrisLoadHumanHeparinCofactorII,1µgperlaneBufferMOPSStandardSeeBluePlus2;Myosin(191kDa),PhosphorylaseB(97kDa),BSA(64kDa),GlutamicDehydrogenase(51kDa),AlcoholDehydrogenase(39kDa),CarbonicAnhydrase(28kDa),MyoglobinRed(19kDa),Lysozyme(14kDa)Overview:HeparincofactorII(HCII)(heparincofactorA,antithrombinBM,dermatansulfatecofactor,humanleuserpin-2)isasinglechainglycoprotein(Mr=65,600,10%carbohydrate)memberoftheserineproteaseinhibitor(serpin)family(1-3).AminoacidsequenceanalysisofheparincofactorIIreveals3potentialN-glycosylationsitesand2sulfatedtyrosineslocatedintwointernalrepeatsof7residueslocatedneartheNH2-terminal(4-6).Theplasmaconcentrationisestimatedtobe90µg/ml(2).Inthecoagulationcascade,heparincofactorIIinhibitsthrombinbyformationofabimolecularcomplexinthepresence(k2=4.5x108M-1min-1)andabsence(k2=5.0x105M-1min-1)ofheparin(2,7-9).ThiscomplexisstabletodenaturantsandessentiallyirreversIBLe.Inadditiontoheparin,awidevarietyofpolyanioniccompoundsaccelerateinhibitionofthrombinbyHCII(3).Noteworthyamongthesecompoundsisdermatansulfate,whichacceleratesinhibitionofthrombinbyHCII,butnotantithrombinIII(1,6)ThisfeaturehasbeenutilizedtodevelopaplasmabasedassayspecificforheparincofactorII.AlthoughHCIIshowsonly~25%sequencehomologytootherserpins,thereactivesitepeptide(COOH-terminal36aminoacids)releasedoninhibitionofthrombinis53%homologoustothatreleasedfromantithrombinIII(ATIII)bythrombin(4,9).ThescissilebondinHCIIisLeu-Serwhichisunusualforanargininespecificproteaseinhibitor(4,9).IncontrasttoATIII,theonlycoagulationproteaseinhibitedbyHCIIisthrombin,OtherproteasesinhibitedbyHCIIincludeα-chymotrypsin,neutrophilcathepsinGandstreptomycesgriseusproteaseB(3).ThemajorphysiologicroleofheparincofactorIImayremaintobediscovered.HeparincofactorIIispreparedfromfreshfrozenplasmabyamodificationoftheprocedureofGriffith,etal.,(9).PurityisassessedonSDSPAGEandactivityisdeterminedbasedonthrombininhibitioninthepresenceofdermatansulfate.HCIIissuppliedin50%(vol/vol)glycerol/H20forstorageat-20°C.Properties:LocalizationPlasmaPlasmaconcentration90µg/ml(2)Modeofactionserineproteaseinhibitor;inhibitsthrombin,a-chymotrypsin,neutrophilcathepsinG,streptomycesgriseusproteaseBMolecularweight65,600(2)ExtinctioncoefficientE1%1cm,280nm=5.93(5)Isoelectricpoint4.95-5.15(2)Structuresinglechainglycoprotein,3potentialN-glycosylationsites,two7-aminoacidresiduerepeats,reactivesitesequence:TVTTVGFMPL-STQVRFTVDR(4)Percentcarbohydrate9.9%(2)Post-translationalmodifications3sulfatedtyrosines
Haematologic Technologies是一家通过ISO 9001:2015认证的公司,是一家主要制造商,专门从事旨在用于体外研究的高质量血浆蛋白的分离和表征的主要制造商。HT的重点是参与凝血级联反应的蛋白质,以及骨代谢的调节。HT产品系列包括150多种高度纯化且特性良好的蛋白质,包括酶原,酶,辅因子和抑制剂,以及单克隆和多克隆抗体的互补产品系列。还提供因子不足的血浆和定制的用于临床研究的定制采血管。提供的服务包括定制蛋白质纯化,蛋白质修饰,分析开发,合同制造和合同研究。
新品排行榜
1
Haematologic Technologies/Human ...
2
Haematologic Technologies/Human ...
3
Haematologic Technologies/Anti-H...
4
Haematologic Technologies/Human ...
5
Haematologic Technologies/Human ...
6
Haematologic Technologies/Human ...
7
Haematologic Technologies/Human ...
8
Haematologic Technologies/Human ...
9
Haematologic Technologies/Human ...
10
Haematologic Technologies/Human ...
文章排行榜
1
上海基剑生物科技有限公司
2
小鼠补体1抑制物抗体 elisa试剂盒
3
Bcl-2 B-cell lymphoma 2试剂盒
4
人血管紧张素Ⅱ受体2抗体AT2R-AbELISA Kit试剂盒
5
人抗甲状腺球蛋白抗体 ATGA TGAB ELISA试剂盒 ELISA kit 检测试剂盒试剂盒
6
小鼠铁蛋白 FE ELISA试剂盒 ELISA kit 检测试剂盒试剂盒
7
Bcl-2 B-cell lymphoma 2试剂盒
8
CiRA00111-ES-H19细胞试剂盒
9
疫苗和病毒载体|宝力泰,haemtech品牌价格 拜力
10
酶联免疫吸附试验 |宝力泰, CD8 细胞株系-试剂盒